Humanized Antibody Mutations for Truncated Amyloid Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current humanized antibodies against amyloid peptides do not effectively bind to N-terminal truncated amyloid peptides, limiting their therapeutic potential for Alzheimer's disease.
Innovation Solution
Development of humanized anti-Aβ antibodies with specific mutations in the heavy and light chain variable domains, allowing for improved binding to N-terminal truncated amyloid peptides such as AβpE3-42 and Aβ4-42.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If humanized versions of NT4X-167 antibody are developed for clinical applications, then therapeutic potential for Alzheimer's disease is improved, but binding activity to N-terminal truncated amyloid peptides is reduced
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations in the framework regions of the heavy and light chain variable domains. These mutations (such as F42A, S45T, N50K, etc. in VH and corresponding mutations in VL) modify the structural and chemical parameters of the antibody, thereby restoring and enhancing binding activity to N-terminal truncated amyloid peptides while maintaining humanized characteristics for clinical use
2Object-affected harmful factors
If standard humanization of NT4X-167 is performed, then immunogenicity in humans is reduced, but binding specificity to AβpE3-42 and Aβ4-42 is lost
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions specifically in the framework regions (FR1, FR2, FR3, FR4) of the variable domains while leaving the CDR regions intact. This localized modification approach allows the antibody to maintain its humanized structure (reducing immunogenicity) while restoring binding specificity through precise local changes in the framework regions that contact the antigen
Data Source
AI summary
The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).